跳至主要内容
临床试验/ITMCTR2100005042
ITMCTR2100005042尚未招募4 期

Homocysteine, inflammatory factors, safety study of scutellarin for injection in patients with acute cerebral infarction - a single center, randomized, open label clinical trial

Yunnan Third People's Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 80(—)
性别
All

入选标准

  • 1. Meet the diagnostic criteria for acute ischemic stroke;
  • 2. Patients with mild to moderate elevation of homocysteine;
  • 3. The time from onset of stroke symptoms or signs to treatment is <=72 hours;
  • 4. The modified Rankin Scale (mRS) score of the first onset or before onset is between 0 and 1;
  • 5.4<=NIHSS score<=15 points;
  • 6. Age 18-80 years old (including 18 and 80 years old), gender is not limited;
  • 7. Voluntarily participate and sign the informed consent.

排除标准

  • 1. Due to encephalitis, brain tumor, brain abscess and diseases that cause similar symptoms;
  • 2. Transient ischemic attack;
  • 3. Patients who are using traditional Chinese medicine injections for promoting blood circulation and removing blood stasis (including Danshen preparations, Ginkgo preparations, and Xuesaitong preparations);
  • 4. Patients who are using folic acid, vitamin B6 or vitamin B12;
  • 5. Have bleeding disorders or bleeding tendency;
  • 6. Patients treated with vascular opening (such as thrombolysis, arterial thrombectomy, ultra-early thrombus aspiration and stenting, etc.) after the onset;
  • 7. Patients with severe disturbance of consciousness (NIHSS 1a consciousness level item >= 2 points);
  • 8) Those with other diseases that affect the function of limb movement, such as claudication, osteoarthritis (active stage), rheumatoid arthritis (active stage), gouty arthritis, etc. The limb movement dysfunction may affect the nerve or functional examination By;
  • 9. Combined with severe cardiovascular disease (New York Heart Function Class (NYHA) grade III and above, unstable angina pectoris, myocardial infarction within 6 months before administration, uncontrolled arrhythmia, etc.);
  • 10. Severe liver and kidney dysfunction;
  • 11. Patients with tumors and other serious diseases of the system;
  • 12. Those who are known to be allergic to the components of the test drug and have allergic constitution;
  • 13. Women who are pregnant, planning to become pregnant or breastfeeding;
  • Patients who participated in other clinical trials within 14.3 months.

研究者

发起方
Yunnan Third People's Hospital

相似试验

Homocysteine, inflammatory factors, safety study of... | 临床试验